Safinamide for Parkinson's disease.
出版信息
Aust Prescr. 2019 Apr;42(2):78-79. doi: 10.18773/austprescr.2019.021. Epub 2018 Feb 28.
Abstract
摘要
相似文献
1
Safinamide for Parkinson's disease.用于治疗帕金森病的沙芬酰胺
Aust Prescr. 2019 Apr;42(2):78-79. doi: 10.18773/austprescr.2019.021. Epub 2018 Feb 28.
2
Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence.沙芬酰胺用于左旋多巴治疗未达稳定状态的帕金森病患者的管理：当前临床证据综述
Ther Clin Risk Manag. 2018 Sep 18;14:1737-1745. doi: 10.2147/TCRM.S139545. eCollection 2018.
3
4
Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.甲磺酸沙芬酰胺治疗中晚期帕金森病的药代动力学药物评价。
Expert Opin Drug Metab Toxicol. 2017 Jun;13(6):693-699. doi: 10.1080/17425255.2017.1329418.
5
Safinamide: A Review in Parkinson's Disease.沙芬酰胺：帕金森病综述
CNS Drugs. 2017 Feb;31(2):169-176. doi: 10.1007/s40263-017-0408-1.
6
[Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].[沙芬酰胺作为帕金森病患者左旋多巴附加治疗的有效性和安全性：非干预性研究]
Fortschr Neurol Psychiatr. 2018 Oct;86(10):624-634. doi: 10.1055/a-0665-4667. Epub 2018 Aug 24.
7
▼ Safinamide for Parkinson's disease.
Drug Ther Bull. 2018 May;56(5):54-57. doi: 10.1136/dtb.2018.5.0623.
8
Investigational agents in the treatment of Parkinson's disease: focus on safinamide.帕金森病治疗中的研究性药物：聚焦于沙芬酰胺
J Exp Pharmacol. 2012 Aug 14;4:85-90. doi: 10.2147/JEP.S34343. eCollection 2012.
9
Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.沙芬酰胺作为左旋多巴的附加疗法用于中晚期帕金森病波动型患者：016研究和SETTLE研究的事后分析
J Parkinsons Dis. 2016;6(1):165-73. doi: 10.3233/JPD-150700.
10
Safinamide (Xadago) for Parkinson's disease.沙芬酰胺（Xadago）用于治疗帕金森病。
Med Lett Drugs Ther. 2017 Sep 11;59(1529):151-153.
引用本文的文献
1
A Stage-Based Approach to Therapy in Parkinson's Disease.帕金森病的阶段治疗方法。
Biomolecules. 2019 Aug 20;9(8):388. doi: 10.3390/biom9080388.
本文引用的文献
1
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.评估依司他宾作为左旋多巴辅助治疗帕金森病运动波动患者的安全性和疗效：一项随机临床试验。
JAMA Neurol. 2017 Feb 1;74(2):216-224. doi: 10.1001/jamaneurol.2016.4467.
2
Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.司来吉兰作为左旋多巴附加治疗中晚期帕金森病的两年随机对照研究。
Mov Disord. 2014 Sep;29(10):1273-80. doi: 10.1002/mds.25961. Epub 2014 Jul 10.
3
Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.随机试验：添加沙芬酰胺治疗伴有运动波动的帕金森病患者的左旋多巴。
Mov Disord. 2014 Feb;29(2):229-37. doi: 10.1002/mds.25751. Epub 2013 Dec 9.
4
Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease.在早期帕金森病中作为附加疗法使用沙芬酰胺的长期疗效和安全性。
Eur J Neurol. 2013 Feb;20(2):271-80. doi: 10.1111/j.1468-1331.2012.03840.x. Epub 2012 Sep 12.
Zotero 插件